| 臺大學術典藏 |
2021-05-21T11:40:30Z |
Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias
|
Su, Kuan Wei; DA-LIANG OU; Fu, Yu Hsuan; HWEI-FANG TIEN; HSIN-AN HOU; LIANG-IN LIN |
| 臺大學術典藏 |
2021-04-21T23:30:44Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
DA-LIANG OU; Chen, Chia Wei; Chia-Lang Hsu; Chung, Chih Hung; Feng, Zi Rui; Lee, Bin Shyun; ANN-LII CHENG; Yang, Muh Hwa; CHIUN HSU |
| 臺大學術典藏 |
2020-07-03T08:45:48Z |
Role of twist in head and neck carcinoma with lymph node metastasis
|
DA-LIANG OU; Chien H.-F; Chen C.-L; Lin T.-C; Lin L.-I. |
| 臺大學術典藏 |
2020-07-03T08:45:47Z |
I�eB kinases increase Myc protein stability and enhance progression of breast cancer cells
|
Yeh P.-Y ;Lu Y.-S ;Da-Liang Ou ;Cheng A.-L.; Yeh P.-Y; Lu Y.-S; DA-LIANG OU; Cheng A.-L. |
| 臺大學術典藏 |
2020-07-03T08:45:47Z |
Induction of DNA damage-inducible gene GADD45�] contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Chen K.-F; Yu S.-L; Da-Liang Ou;Shen Y.-C;Yu S.-L;Chen K.-F;Yeh P.-Y;Fan H.-H;Feng W.-C;Wang C.-T;Lin L.-I;Hsu C;Cheng A.-L.; DA-LIANG OU; Shen Y.-C; Yeh P.-Y; Fan H.-H; Feng W.-C; Wang C.-T; Lin L.-I; Hsu C; Cheng A.-L. |
| 臺大學術典藏 |
2020-07-03T08:45:47Z |
CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia
|
Lin T.-C; Hou H.-A; Chou W.-C; DA-LIANG OU; Yu S.-L; Tien H.-F; Lin L.-I.; Lin T.-C ;Hou H.-A ;Chou W.-C ;Da-Liang Ou ;Yu S.-L ;Tien H.-F ;Lin L.-I. |
| 臺大學術典藏 |
2020-07-03T08:45:44Z |
MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine
|
Lu J.-W;Lin Y.-M;Lai Y.-L;Chen C.-Y;Hu C.-Y;Tien H.-F;Da-Liang Ou;Lin L.-I.; Lu J.-W; Lin Y.-M; Lai Y.-L; Chen C.-Y; Hu C.-Y; Tien H.-F; DA-LIANG OU; Lin L.-I. |
| 臺大學術典藏 |
2020-07-03T08:45:44Z |
Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Feng Z.-R; Liou J.-Y; Fan H.-H; Lee B.-S; Hsu C; Cheng A.-L.Ann-Lii; Lin L.-I; Shyue S.-K; Da-Liang Ou;Shyue S.-K;Lin L.-I;Feng Z.-R;Liou J.-Y;Fan H.-H;Lee B.-S;Hsu C;Cheng A.-L.Ann-Lii; DA-LIANG OU |
| 臺大學術典藏 |
2020-07-03T08:45:43Z |
Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)
|
Lu J.-W;Wang A.-N;Liao H.-A;Chen C.-Y;Hou H.-A;Hu C.-Y;Tien H.-F;Da-Liang Ou;Lin L.-I.; Lu J.-W; Wang A.-N; Liao H.-A; Chen C.-Y; Hou H.-A; Hu C.-Y; Tien H.-F; DA-LIANG OU; Lin L.-I. |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y;Chen B.-B;Da-Liang Ou;Lin Z.-Z;Hsu C.-H;Wang M.-J;Cheng A.-L;Hsu C.; Shao Y.-Y; Chen B.-B; DA-LIANG OU; Lin Z.-Z; Hsu C.-H; Wang M.-J; Cheng A.-L; Hsu C. |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy
|
Lin Y.-Z;Da-Liang Ou;Chang H.-Y;Lin W.-Y;Hsu C;Chang P.-L.; Lin Y.-Z; DA-LIANG OU; Chang H.-Y; Lin W.-Y; Hsu C; Chang P.-L. |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y;Tan C.-T;Chen C.-W;Da-Liang Ou;Cheng A.-L;Hsu C.; Lin Y.-Y; Tan C.-T; Chen C.-W; DA-LIANG OU; Cheng A.-L; Hsu C. |
| 臺大學術典藏 |
2020-07-03T08:45:41Z |
TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
|
Lai H.-H;Li C.-W;Hong C.-C;Sun H.-Y;Chiu C.-F;Da-Liang Ou;Chen P.-S.; Lai H.-H; Li C.-W; Hong C.-C; Sun H.-Y; Chiu C.-F; DA-LIANG OU; Chen P.-S. |
| 臺大學術典藏 |
2020-07-03T08:45:40Z |
Mouse models for immunotherapy in hepatocellular carcinoma
|
Li E;Lin L;Chen C.-W;Da-Liang Ou; Li E; Lin L; Chen C.-W; DA-LIANG OU |
| 臺大學術典藏 |
2019 |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Da-Liang Ou;Lin Y.-Y;Hsu C.-L;Lin Y.-Y;Chen C.-W;Yu J.-S;Miaw S.-C;Hsu P.-N;Cheng A.-L;Hsu C.; DA-LIANG OU; Lin Y.-Y; Hsu C.-L; Lin Y.-Y; Chen C.-W; Yu J.-S; Miaw S.-C; Hsu P.-N; Cheng A.-L; Hsu C. |
| 臺大學術典藏 |
2018-09-10T09:22:43Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin, Yu-Lin;Liau, Jau-Yu;Yu, Shan-Chi;Ou, Da-Liang;Lin, Liang-In;Tseng, Li-Hui;Chang, Yih-Leong;Yeh, Kun-Huei;Cheng, Ann-Lii; Lin, Y.-L. and Liau, J.-Y. and Yu, S.-C. and Ou, D.-L. and Lin, L.-I. and Tseng, L.-H. and Chang, Y.-L. and Yeh, K.-H. and Cheng, A.-L.; 林亮音 ;曾麗慧 ;張逸良 ;林育麟 ;鄭安理 ;葉坤輝 ;歐大諒 ;尤善琦 ;廖肇裕; 林亮音 ;曾麗慧 ;張逸良 ;林育麟 ;鄭安理 ;葉坤輝 ;歐大諒 ;尤善琦 ;廖肇裕; Lin, Yu-Lin; LI-HUI TSENG; Lin, Yu-Lin; Liau, Jau-Yu; YIH-LEONG CHANG; JAU-YU LIAU; Yu, Shan-Chi; Ou, Da-Liang; DA-LIANG OU; Ou, Da-Liang; LIANG-IN LIN; Lin, Liang-In; Lin, Liang-In; Tseng, Li-Hui; KUN-HUEI YEH; Tseng, Li-Hui; Chang, Yih-Leong; YU-LIN LIN; Yeh, Kun-Huei; ANN-LII CHENG; Yeh, Kun-Huei; Cheng, Ann-Lii; Cheng, Ann-Lii; Cheng, Ann-Lii |
